Article | Published:

Two-dimensional infrared spectroscopy reveals the complex behaviour of an amyloid fibril inhibitor

Nature Chemistry volume 4, pages 355360 (2012) | Download Citation

Abstract

Amyloid formation has been implicated in the pathology of over 20 human diseases, but the rational design of amyloid inhibitors is hampered by a lack of structural information about amyloid–inhibitor complexes. We use isotope labelling and two-dimensional infrared spectroscopy to obtain a residue-specific structure for the complex of human amylin (the peptide responsible for islet amyloid formation in type 2 diabetes) with a known inhibitor (rat amylin). Based on its sequence, rat amylin should block formation of the C-terminal β-sheet, but at 8 h after mixing, rat amylin blocks the N-terminal β-sheet instead. At 24 h after mixing, rat amylin blocks neither β-sheet and forms its own β-sheet, most probably on the outside of the human fibrils. This is striking, because rat amylin is natively disordered and not previously known to form amyloid β-sheets. The results show that even seemingly intuitive inhibitors may function by unforeseen and complex structural processes.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353–356 (2002).

  2. 2.

    , , & Pancreatic islet cell toxicity of amylin associated with type 2 diabetes mellitus. Nature 368, 756–760 (1994).

  3. 3.

    & Molecular pathways of neurodegeneration in Parkinson's disease. Science 302, 819–822 (2003).

  4. 4.

    et al. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nature. Med. 12, 801–808 (2006).

  5. 5.

    & Escaping amyloid fate. Nature. Struct. Mol. Biol. 15, 544–546 (2008).

  6. 6.

    et al. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nature. Med. 4, 822–826 (1998).

  7. 7.

    , & Design and characterization of a membrane permeable N-methyl amino acid-containing peptide that inhibits Aβ1–40 fibrillogenesis. J. Pep. Res. 60, 37–55 (2002).

  8. 8.

    , & Structure-based design and study of non-amyloidogenic, double N-methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity. J. Mol. Biol. 315, 339–350 (2002).

  9. 9.

    & Inhibition of amyloid fibril formation by peptide analogues modified with α-aminoisobutyric acid. Angew. Chem. Int. Ed. 43, 4041–4044 (2004).

  10. 10.

    , , , & Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis. Proc. Natl Acad. Sci. USA 103, 2046–2051 (2006).

  11. 11.

    , & Combination of kinetically selected inhibitors in trans leads to highly effective inhibition of amyloid formation. J. Am. Chem. Soc. 132, 14340–14342 (2010).

  12. 12.

    , , & The ability of rodent islet amyloid polypeptide to inhibit amyloid formation by human islet amyloid polypeptide has important implications for the mechanism of amyloid formation and the design of inhibitors. Biochemistry 49, 872–881 (2010).

  13. 13.

    et al. Macrocyclic β-sheet peptides that inhibit the aggregation of a Tau-protein-derived hexapeptide. J. Am. Chem. Soc. 133, 3144–3157 (2011).

  14. 14.

    et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with Type 2 diabetes. Diabetes Care 26, 784–790 (2003).

  15. 15.

    Mechanisms of amyloid fibril self-assembly and inhibition. FEBS J. 272, 5971–5978 (2005).

  16. 16.

    , , & Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 282, 10311–10324 (2007).

  17. 17.

    , & Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug Des. 67, 27–37 (2006).

  18. 18.

    et al. Structural and mechanistic basis behind the inhibitory interaction of PcTS on α-synuclein amyloid fibril formation. Proc. Natl Acad. Sci. USA 106, 21057–21062 (2009).

  19. 19.

    et al. Inhibitors of amyloid toxicity based on β-sheet packing of Aβ40 and Aβ42. Biochemistry 45, 5503–5516 (2006).

  20. 20.

    et al. The binding of thioflavin T and its neutral analog BTA-1 to protofibrils of the Alzheimer's disease Aβ16–22 peptide probed by molecular dynamics simulations. J. Mol. Biol. 384, 718–729 (2008).

  21. 21.

    et al. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature 475, 96–100 (2011).

  22. 22.

    , , & Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR. Biochemistry 46, 13505–13522 (2007).

  23. 23.

    et al. Atomic structure of the cross-β spine of islet amyloid polypeptide (amylin). Protein Sci. 17, 1467–1474 (2008).

  24. 24.

    et al. Polymorphic fibrillar assembly of human amylin. J. Struct. Biol. 119, 17–27 (1997).

  25. 25.

    , , , & Strategies for extracting structural information from 2D IR spectroscopy of amyloid: application to islet amyloid polypeptide. J. Phys. Chem. B 113, 15679–15691 (2009).

  26. 26.

    , , & 2D IR provides evidence for mobile water molecules in β-amyloid fibrils. Proc. Natl Acad. Sci. USA 106, 17751–17756 (2009).

  27. 27.

    et al. Two-dimensional IR spectroscopy and isotope labeling defines the pathway of amyloid formation with residue-specific resolution. Proc. Natl Acad. Sci. USA 106, 6614–6619 (2009).

  28. 28.

    et al. Identification of a novel human islet amyloid polypeptide β-sheet domain and factors influencing fibrillogenesis. J. Mol. Biol. 308, 515–525 (2001).

  29. 29.

    et al. 2DIR spectroscopy of human amylin fibrils reveals robust β-sheet structure. J. Am. Chem. Soc. 133, 16062–16071 (2011).

  30. 30.

    & Lipid membranes modulate the structure of islet amyloid polypeptide. Biochemistry 44, 12113–12119 (2005).

  31. 31.

    , & Conserved and cooperative assembly of membrane-bound α-helical states of islet amyloid polypeptide. Biochemistry 45, 9496–9508 (2006).

  32. 32.

    , , , & Two-dimensional infrared spectroscopy provides evidence of an intermediate in the membrane-catalyzed assembly of diabetic amyloid. J. Phys. Chem. B 113, 2498–2505 (2009).

  33. 33.

    et al. Solution structures of rat amylin peptide: simulation, theory, and experiment. Biophys. J. 98, 443–451 (2010).

  34. 34.

    , , & Coherent two dimensional infrared spectroscopy of a cyclic decapeptide antamanide. A simulation study of the amide-I and A bands. J. Phys. Chem. B 112, 12479–12490 (2008).

  35. 35.

    et al. 2D IR line shapes probe ovispirin peptide conformation and depth in lipid bilayers. J. Am. Chem. Soc. 132, 2832–2838 (2010).

  36. 36.

    et al. Melting of a β-hairpin peptide using isotope-edited 2D IR spectroscopy and simulations. J. Phys. Chem. B 114, 10913–10924 (2010).

  37. 37.

    , , , & β-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood–brain barrier permeability and resistance to proteolytic degradation in plasma. J. Neurobiol. 39, 371–382 (1999).

  38. 38.

    & Peptide and protein mimetics inhibiting amyloid β-peptide aggregation. Acc. Chem. Res. 41, 1309–1318 (2008).

  39. 39.

    , , & Suppression of IAPP fibrillation at anionic lipid membranes via IAPP-derived amyloid inhibitors and insulin. Biophys. Chem. 150, 73–79 (2010).

  40. 40.

    , & A single-point mutation converts the highly amyloidogenic human islet amyloid polypeptide into a potent fibrillization inhibitor. J. Am. Chem. Soc. 129, 11300–11301 (2007).

  41. 41.

    , , & Two-dimensional infrared spectra of isotopically diluted amyloid fibrils from Aβ40. Proc. Natl Acad. Sci. USA 105, 7720–7725 (2008).

  42. 42.

    et al. Intermolecular structure determination of amyloid fibrils with magic-angle spinning and dynamic nuclear polarization NMR. J. Am. Chem. Soc. 133, 13967–13974 (2011).

  43. 43.

    , , & Picosecond dynamics of a membrane protein revealed by 2D IR. Proc. Natl Acad. Sci. USA 103, 3528–3533 (2006).

  44. 44.

    , , , & Amide vibrations are delocalized across the hydrophobic interface of a transmembrane helix dimer. Proc. Natl Acad. Sci. USA 103, 16740–16745 (2006).

  45. 45.

    et al. Gating mechanism of the influenza A M2 channel revealed by 1D and 2D IR spectroscopies. Structure 17, 247–254 (2009).

  46. 46.

    , , & Tidal surge in the M2 proton channel, sensed by 2D IR spectroscopy. Proc. Natl Acad. Sci. USA 108, 6115–6120 (2011).

  47. 47.

    , , , & Residue-specific vibrational echoes yield 3D structures of a transmembrane helix dimer. Science 332, 1206–1209 (2011).

  48. 48.

    et al. Two-dimensional IR spectroscopy and segmental 13C labeling reveals the domain structure of human γD-crystallin amyloid fibrils. Proc. Natl Acad. Sci. USA (2012).

  49. 49.

    , , & Couplings between peptide linkages across a 310-helical hydrogen bond revealed by two-dimensional infrared spectroscopy. J. Am. Chem. Soc. 131, 2042–2043 (2009).

  50. 50.

    & Incorporation of pseudoproline derivatives allows the facile synthesis of human IAPP, a highly amyloidogenic and aggregation-prone polypeptide. Org. Lett. 7, 693–696 (2005).

  51. 51.

    , , , & Efficient microwave-assisted synthesis of human islet amyloid polypeptide designed to facilitate the specific incorporation of labeled amino acids. Org. Lett. 12, 4848–4851 (2010).

  52. 52.

    et al. A simple and economical method for the production of 13C,18O-labeled Fmoc-amino acids with high levels of enrichment: applications to isotope-edited IR studies of proteins. Org. Lett. 9, 4935–4937 (2007).

  53. 53.

    , , & Residue-specific structural kinetics of proteins through the union of isotope labeling, mid-IR pulse shaping, and coherent 2D IR spectroscopy. Methods 52, 12–22 (2010).

  54. 54.

    , & Generation and characterization of phase and amplitude shaped femtosecond mid-IR pulses. Opt. Express 14, 13120–13130 (2006).

  55. 55.

    & How to turn your pump–probe instrument into a multidimensional spectrometer: 2D IR and Vis spectroscopies via pulse shaping. Phys. Chem. Chem. Phys. 11, 748–761 (2009).

Download references

Acknowledgements

Support for this research was provided by the National Institutes of Health (grants DK79895 to M.T.Z., GM078114 to D.P.R. and DK088184 to J.J.d.P.) and the National Science Foundation (CRC grant CHE 0832584 to M.T.Z and D.P.R.). The authors are grateful to R. Tycko for providing the coordinates for his structural model of human amylin fibrils.

Author information

Affiliations

  1. Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706-1396, USA

    • Chris T. Middleton
    • , Ann Marie Woys
    •  & Martin T. Zanni
  2. Department of Chemistry, State University of New York at Stony Brook, Stony Brook, New York 11794-3400, USA

    • Peter Marek
    • , Ping Cao
    •  & Daniel P. Raleigh
  3. Department of Chemical Engineering, University of Wisconsin-Madison, Madison, Wisconsin 53706-1396, USA

    • Chi-cheng Chiu
    • , Sadanand Singh
    •  & Juan J. de Pablo

Authors

  1. Search for Chris T. Middleton in:

  2. Search for Peter Marek in:

  3. Search for Ping Cao in:

  4. Search for Chi-cheng Chiu in:

  5. Search for Sadanand Singh in:

  6. Search for Ann Marie Woys in:

  7. Search for Juan J. de Pablo in:

  8. Search for Daniel P. Raleigh in:

  9. Search for Martin T. Zanni in:

Contributions

C.T.M., D.P.R. and M.T.Z. designed the research. C.T.M. performed the 2D IR and electron microscopy measurements. P.M., A.W.M. and P.C. synthesized and purified peptides. P.M and P.C performed the thioflavin-T fluorescence measurements. C.C., S.S. and J.J.d.P. designed and performed the molecular dynamics simulations. C.T.M. and M.T.Z. analysed data. C.T.M., D.P.R. and M.T.Z. wrote the manuscript and coordinated contributions by other authors.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Martin T. Zanni.

Supplementary information

PDF files

  1. 1.

    Supplementary information

    Supplementary information

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nchem.1293

Further reading